Last reviewed · How we verify

Canagliflozin (TA-7284)

Tanabe Pharma Corporation · FDA-approved active Small molecule

Canagliflozin (TA-7284) is a SGLT2 inhibitor Small molecule drug developed by Tanabe Pharma Corporation. It is currently FDA-approved for Type 2 diabetes mellitus.

Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.

Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.

At a glance

Generic nameCanagliflozin (TA-7284)
SponsorTanabe Pharma Corporation
Drug classSGLT2 inhibitor
TargetSGLT2 (sodium-glucose cotransporter 2)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, canagliflozin prevents glucose from being reabsorbed back into the bloodstream, allowing excess glucose to be excreted in the urine. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Canagliflozin (TA-7284)

What is Canagliflozin (TA-7284)?

Canagliflozin (TA-7284) is a SGLT2 inhibitor drug developed by Tanabe Pharma Corporation, indicated for Type 2 diabetes mellitus.

How does Canagliflozin (TA-7284) work?

Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.

What is Canagliflozin (TA-7284) used for?

Canagliflozin (TA-7284) is indicated for Type 2 diabetes mellitus.

Who makes Canagliflozin (TA-7284)?

Canagliflozin (TA-7284) is developed and marketed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

What drug class is Canagliflozin (TA-7284) in?

Canagliflozin (TA-7284) belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is Canagliflozin (TA-7284) in?

Canagliflozin (TA-7284) is FDA-approved (marketed).

What are the side effects of Canagliflozin (TA-7284)?

Common side effects of Canagliflozin (TA-7284) include Genital mycotic infections, Urinary tract infections, Polyuria, Thirst, Diabetic ketoacidosis.

What does Canagliflozin (TA-7284) target?

Canagliflozin (TA-7284) targets SGLT2 (sodium-glucose cotransporter 2) and is a SGLT2 inhibitor.

Related